MedTrace Logo

Treatment of Post-Punch Biopsy Bleeding in Apixaban-Treated Patients Using Self-Administered BXP154B

NCT06205615 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-03-18

No results posted yet for this study

Summary

The goal of this clinical trial is to test if the study drug, BXP154B works to stop bleeding from a minor wound in patients that are on apixaban for anticoagulant therapy. The main questions it aims to answer are:

* How long does it take to stop bleeding after BXP154B is applied to a wound?
* How many people require the use of a rescue treatment to stop bleeding?
* Does BXP154B reduce instances of re-bleeding after the bleeding has stopped initially?
* Is BXP154B safe and well-tolerated?

Conditions

  • Wound Bleeding

Interventions

DRUG

BXP154B

BXP154B will be self-administered topically following wound induction

DRUG

Placebo

Placebo will be self-administered topically following wound induction

PROCEDURE

Punch Biopsy

Punch biopsy to leg

Sponsors & Collaborators

  • Bio 54, LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-24
Primary Completion
2024-03-14
Completion
2024-03-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06205615 on ClinicalTrials.gov